
1. int j parasitol drugs drug resist. 2017 apr;7(1):42-50. doi:
10.1016/j.ijpddr.2016.12.005. epub 2016 dec 23.

effect clinically approved hdac inhibitors plasmodium, leishmania and
schistosoma parasite growth.

chua mj(1), arnold ms(1), xu w(2), lancelot j(3), lamotte s(4), späth gf(4),
prina e(4), pierce rj(3), fairlie dp(2), skinner-adams ts(1), andrews kt(5).

author information: 
(1)griffith institute drug discovery, griffith university, queensland,
australia.
(2)institute molecular bioscience, university queensland, brisbane,
4072, australia.
(3)univ. lille, cnrs, inserm, chu lille, institut pasteur de lille, u1019 - umr
8204- ciil -centre d'infection et d'immunité de lille, f-59000 lille, france.
(4)institut pasteur inserm u1201, unité de parasitologie moléculaire et
signalisation, paris, france.
(5)griffith institute drug discovery, griffith university, queensland,
australia. electronic address: k.andrews@griffith.edu.au.

malaria, schistosomiasis leishmaniases among prevalent tropical 
parasitic diseases requires new innovative treatments. targeting
essential parasite pathways, regulate gene expression cell
cycle progression, key strategy discovering new drug leads. this
study, four clinically approved anti-cancer drugs (vorinostat, belinostat,
panobinostat romidepsin) target histone/lysine deacetylase enzymes 
examined in vitro activity plasmodium knowlesi, schistosoma mansoni, 
leishmania amazonensis l. donovani parasites two in vivo activity 
a mouse malaria model. four compounds potent inhibitors p. knowlesi
malaria parasites (ic50 9-370 nm), belinostat, panobinostat vorinostat
having 8-45 fold selectivity parasite human neonatal foreskin
fibroblast (nff) human embryonic kidney (hek 293) cells, romidepsin 
not selective. hdac inhibitor drugs caused hyperacetylation of
p. knowlesi histone h4. none drugs active leishmania
amastigote promastigote parasites (ic50 > 20 μm) s. mansoni schistosomula
(ic50 > 10 μm), however romidepsin inhibited s. mansoni adult worm parings and
egg production (ic50 ∼10 μm). modest in vivo activity observed p. berghei 
infected mice dosed orally vorinostat panobinostat (25 mg/kg twice daily 
for four days), significant reduction parasitemia observed days 4-7 
and 4-10 infection (p < 0.05), respectively.

copyright © 2017 authors. published elsevier ltd.. rights reserved.

doi: 10.1016/j.ijpddr.2016.12.005 
pmcid: pmc5241585
pmid: 28107750  [indexed medline]

